Leader: Stefano Calciolari (UNIMIB); Other collaborator(s): Alberto Pilotto (UNIBA), Bellelli Giuseppe, Ferrarese Carlo, Francesca Gasparini (UNIMIB), Maggi Stefania (CNR Neuroscience Institute, Aging Branch), Luca Francioso (CNR)
WP1, WP2 and WP3 involve excellent trials of innovative interventions aimed to improve the wellbeing of elderly in three different care settings: community, hospital and long-term care, respectively. Though these initiatives are clinically and socially important per se, their policy relevance also depends on the capacity of informing decision makers about their opportunity cost. Therefore, we will conduct three separate cost-effectiveness analyses of the multicomponent interventions implemented in the three mentioned WPs, by measuring the resources used and relevant outcomes associated with each intervention.
We will adopt a health system perspective to define the inclusion criteria for resources used, trying to extend it to a societal perspective whenever feasible. This will allow us to integrate in a synthetic perspective the clinical and economic rationality of the health technologies embedded in three novel initiatives.
Brief description of the activities and of the intermediate results
Contacts established with the clinical liaisons of WP1, WP2, WP3 and preliminary agreement reached on:
All these decisions will be taken based on the study design of the three trials, in agreement with clinical liaisons of WP1, WP2, WP3.
Main policy, industrial and scientific implications
The identification of the resources involved in the interventions will allow to understand the economic implications of the proposed clinical innovations and their scalability
Brief description of the activities and of the intermediate results
Discussions with the clinical liaisons of WP1 and WP2 to:
Main policy, industrial and scientific implications
The identification of the resources involved in the interventions will allow to understand the economic implications of the proposed clinical innovations and their scalability.
Brief description of the activities and of the intermediate results
Discussions with the clinical liaisons of WP3 to:
Definition of the data matrixes to be populated and used in cost-effectiveness analyses. Initial reflection on the unit prices to be used for evaluating the resources used in each initiative.
Main policy, industrial and scientific implications
The identification of the resources involved in the interventions will allow to understand the economic implications of the proposed clinical innovations and their scalability.
Brief description of the activities and of the intermediate results
Main policy, industrial and scientific implications
The identification of the resources involved in the interventions, and their unit costs, will allow to assess the economic implications of the innovative clinical interventions and their scalability.